These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 22968160)

  • 1. Fluoroquinolones in the treatment of bronchopulmonary disease in cystic fibrosis.
    Hurley M; Smyth A
    Ther Adv Respir Dis; 2012 Dec; 6(6):363-73. PubMed ID: 22968160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of Pseudomonas aeruginosa lung infection in Danish cystic fibrosis patients.
    Pedersen SS; Jensen T; Høiby N; Koch C; Flensborg EW
    Acta Paediatr Scand; 1987 Nov; 76(6):955-61. PubMed ID: 3425313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis.
    Hurley MN; Smith S; Forrester DL; Smyth AR
    Cochrane Database Syst Rev; 2020 Jul; 7(7):CD008037. PubMed ID: 32671834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microbiology of lung infection in cystic fibrosis.
    Govan JR; Nelson JW
    Br Med Bull; 1992 Oct; 48(4):912-30. PubMed ID: 1281036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The treatment of respiratory pseudomonas infection in cystic fibrosis: what drug and which way?
    Banerjee D; Stableforth D
    Drugs; 2000 Nov; 60(5):1053-64. PubMed ID: 11129122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on treatment of pulmonary exacerbations in cystic fibrosis.
    Smyth A
    Curr Opin Pulm Med; 2006 Nov; 12(6):440-4. PubMed ID: 17053495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tobramycin therapy of pulmonary infections in patients with cystic fibrosis.
    Hawley HB; Lewis RM; Swartz DR; Gump DW
    Curr Ther Res Clin Exp; 1974 May; 16(5):414-23. PubMed ID: 4209057
    [No Abstract]   [Full Text] [Related]  

  • 8. Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis.
    Smith S; Ratjen F; Remmington T; Waters V
    Cochrane Database Syst Rev; 2020 May; 5(5):CD006961. PubMed ID: 32412092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis.
    Waters V; Ratjen F
    Cochrane Database Syst Rev; 2017 Jun; 6(6):CD006961. PubMed ID: 28628280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibiotic therapy in cystic fibrosis. Evaluation of efficacy.
    Levy J
    Chest; 1988 Aug; 94(2 Suppl):150S-156S. PubMed ID: 3135160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy and safety of cefepime in the treatment of bronchopulmonary disease exacerbation in pediatric patients with mucoviscidosis].
    Semykin SIu; Postnikov SS; Polikarpova SV; Dubovik LG; Kolbatova ES
    Antibiot Khimioter; 2005; 50(4):18-22. PubMed ID: 16392335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exacerbations in cystic fibrosis: 3--Management.
    Smyth A; Elborn JS
    Thorax; 2008 Feb; 63(2):180-4. PubMed ID: 18234661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimicrobial peptide therapeutics for cystic fibrosis.
    Zhang L; Parente J; Harris SM; Woods DE; Hancock RE; Falla TJ
    Antimicrob Agents Chemother; 2005 Jul; 49(7):2921-7. PubMed ID: 15980369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efficacy and safety of cefoperazone/sulbactam in the treatment of children with mucoviscidosis during exacerbation of the bronchopulmonary process].
    Semykin SIu; Postnikov SS; Polikarpova SV; Perederko LV
    Antibiot Khimioter; 2003; 48(12):18-21. PubMed ID: 15176099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors influencing the acquisition and eradication of early Pseudomonas aeruginosa infection in cystic fibrosis.
    Jackson L; Waters V
    J Cyst Fibros; 2021 Jan; 20(1):8-16. PubMed ID: 33172756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro prevention of Pseudomonas aeruginosa early biofilm formation with antibiotics used in cystic fibrosis patients.
    Fernández-Olmos A; García-Castillo M; Maiz L; Lamas A; Baquero F; Cantón R
    Int J Antimicrob Agents; 2012 Aug; 40(2):173-6. PubMed ID: 22727530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microbiological rationale for the utilisation of prulifloxacin, a new fluoroquinolone, in the eradication of serious infections caused by Pseudomonas aeruginosa.
    Roveta S; Schito AM; Marchese A; Schito GC
    Int J Antimicrob Agents; 2005 Nov; 26(5):366-72. PubMed ID: 16216467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
    Smith S; Waters V; Jahnke N; Ratjen F
    Cochrane Database Syst Rev; 2020 Jun; 6(6):CD009528. PubMed ID: 32520436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
    Waters V; Ratjen F
    Cochrane Database Syst Rev; 2017 Oct; 10(10):CD009528. PubMed ID: 28981972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maintenance treatment with antibiotics in cystic fibrosis patients. Sense or nonsense?
    Hodson ME
    Neth J Med; 1995 Jun; 46(6):288-92. PubMed ID: 7643944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.